Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Cancer Non-resectable × folfirinox × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 45 Neoplasms 6 Colorectal Neoplasms 5 Neoplasm Metastasis 4 Adenocarcinoma 3 Resectable Pancreatic Cancer 2 Rectal Neoplasms 2 Pancreatic Cancer Metastatic 2 Carcinoma, Hepatocellular 2 Biliary Tract Neoplasms 2 Urachal cancer 1 Stomach Neoplasms 1 Pancreatic Ductal Adenocarcinoma (PDAC) 1 Pancreatic Cancer Non-resectable 1 Pancreatic Adenocarcinoma 1 Neoplasms, Basal Cell 1 Locally Advanced Unresectable or Metastatic Solid Tumors 1 Locally Advanced Pancreatic Adenocarcinoma 1 Localized Pancreatic Adenocarcinoma 1 Gastrointestinal Neoplasms 1 Gastroesophageal Adenocarcinoma 1 Gastro-enteropancreatic neuroendocrine tumor 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Cancer Metastatic 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Islet Cell 1 Carcinoma 1 Borderline Resectable Pancreatic Cancer 1

Interventions

Gemcitabine 3 Leucovorin 2 Fluorouracil 2 tremelimumab 1 pamrevlumab 1 irinotecan sucrosofate 1 folfirinox 1 durvalumab 1 Taxes 1 Specimen Handling 1 Radiosurgery 1 Oxaliplatin 1 Medical Marijuana 1 Irinotecan 1 Heavy Ion Radiotherapy 1 Chemoradiotherapy 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03941093 2024-11-05

LAPIS

Kyntra Bio

Phase 3 Completed

284 enrolled 14 charts

Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon ⚡